Epigeneres Biotech Pvt. has developed a blood test that can detect all types of cancer (200 types) in the first stage itself. This innovative test has received a patent from the US and will be launched in the American market soon.
The company has already launched the test in London, UK, and Mumbai, India, at price points of 900 pounds plus VAT and Rs 14,000 plus GST per test, respectively, Ashish Tripathi, chairman of Epigeneres Biotech, told NDTV Profit.
The blood test is a breakthrough technology in cancer detection and has the potential to revolutionise the way cancer is diagnosed and treated, he said. "Our test can detect cancer cells at a very early stage that enables doctors to take prompt action and increase the chances of successful treatment."
The company is in talks with global investors to raise in excess of $200 million for expansion and plans to use the funds to further develop its technology and increase its market reach, Tripathi said.
Two studies at the National Health Service in the UK are currently underway, which are expected to further increase the growth prospects of the company.
What's remarkable about Epigeneres Biotech's achievement is that it has looked at a different causative marker, which none of the global giants in this space have looked at to date. The revenue potential for this breakthrough technology runs into billions of dollars, making it an attractive investment opportunity, Tripathi said.
Essential Business Intelligence, Continuous LIVE TV, Sharp Market Insights, Practical Personal Finance Advice and Latest Stories — On NDTV Profit.
